Kuznicki Law is investigating the proposed sale of Alpine Immune Sciences, Inc. (NasdaqGM: ALPN) to Vertex Pharmaceuticals Incorporated (NasdaqGS: VRTX). Under the terms of the proposed transaction, shareholders of Alpine will receive $65.00 in cash for each share of Alpine that they own. Kuznicki Law is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Please note that the transaction is structured as a tender offer, such that time may be of the essence.